Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

BACKGROUND: Immune checkpoint inhibitors (ICI) either alone or in combination with chemotherapy have expanded our choice of agents for the palliative treatment of non-small cell lung cancer (NSCLC) patients. Unfortunately, not all patients will experience favorable response to treatment with ICI and...

Descripción completa

Detalles Bibliográficos
Autores principales: Brueckl, Wolfgang M., Ficker, Joachim H., Zeitler, Gloria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713034/
https://www.ncbi.nlm.nih.gov/pubmed/33272262
http://dx.doi.org/10.1186/s12885-020-07690-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713034/
https://www.ncbi.nlm.nih.gov/pubmed/33272262
http://dx.doi.org/10.1186/s12885-020-07690-8

Ejemplares similares